Pacira BioSciences (NASDAQ: PCRX)
Pacira BioSciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Pacira BioSciences Company Info
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
News & Analysis
Why Pacira Biosciences Stock Sank Today
A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug.
After a Label Expansion, Is This Under-the-Radar Biotech a Buy?
This healthcare stock just got great news from the Food and Drug Administration.
Why Pacira BioSciences Is Soaring Today
Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.
Pacira BioSciences Rocks in Q1 With Strong Momentum for Pain Drug Exparel
The small drugmaker posted record sales for its flagship drug in the first quarter.
Why Heron Therapeutics and Pacira BioSciences Are Moving in Opposite Directions Today
Heron's pain is Pacira's gain.
Why Pacira Pharmaceuticals Stock Is on the Rise Today
The company's shares are rallying today on an analyst upgrade.
Why SUPERVALU, GOL, and Pacira Pharmaceuticals Jumped Today
Find out how these stocks escaped the carnage on Wall Street.
The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much as 24%
Despite a mixed third-quarter report, Pacira topped Wall Street's expectations where it counts.
Valuation
Podcast Episodes
Can Drugmakers Cure the Opioid Crisis?
Deaths from prescription opioids have quadrupled since 1999, but new drugs that reduce their use may help end the opioid epidemic.
Top Stocks That Are Already Crushing the Market in 2017
Exelixis, Pacira Pharmaceuticals, Kite Pharma, Exact Sciences, and Portola Pharmaceuticals are up more than 50% in the first two months of 2017.
Earnings Transcripts
Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript
PCRX earnings call for the period ending September 30, 2021.
Pacira BioSciences, inc (PCRX) Q2 2021 Earnings Call Transcript
PCRX earnings call for the period ending June 30, 2021.
Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript
PCRX earnings call for the period ending March 31, 2021.
Pacira BioSciences, Inc. (PCRX) Q4 2020 Earnings Call Transcript
PCRX earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.